Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its mechanism of action is not fully understood but may involve direct relaxation of vascular smooth muscle.
## Primary Indications
* Treatment of peripheral vascular diseases such as intermittent claudication and Raynaud's disease.
* To improve blood flow in conditions associated with vasospasm.
## Adult Dosing
* **Intermittent Claudication/Peripheral Vascular Disease:** 10 mg to 20 mg orally every 3 to 4 times daily.
* **Dosage Titration:** Doses may be increased gradually up to 40 mg every 3 to 4 times daily as tolerated and based on patient response.
## Pediatric Dosing
* There is no established pediatric dosing for isoxsuprine hydrochloride. Use in children is generally not recommended.
## Dose Adjustments
* **Renal Impairment:** Use with caution. No specific dose adjustments are provided; monitor for adverse effects.
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are provided; monitor for adverse effects.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Use in patients with congenital heart disease or arrhythmias.
* Should not be administered immediately postpartum or in patients with significant hypotension.
## Adverse Effects
* **Common:** Nausea, vomiting, gastric distress, dizziness, weakness, nervousness, flushing, drowsiness.
* **Less Common:** Hypotension, tachycardia, rash, epigastric distress.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive drugs, leading to excessive hypotension. Use with caution and monitor blood pressure closely.
* **Other Vasodilators:** Concurrent use with other vasodilators may increase the risk of hypotension.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease improvement.
* Patient-reported adverse effects.
## Clinical Pearls
* The efficacy of isoxsuprine in peripheral vascular disease is controversial and not well-supported by robust clinical trials.
* Its use should be considered only after other, more proven therapies have been attempted or are not suitable.
* Patients should be advised to report any dizziness or hypotensive symptoms.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and indications can vary.
